Booster vaccines reduced the risk of COVID‑19–related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research led by the ...

While this year’s Super Bowl will be filled with more pharma ads than ever before, one big name will be missing from the roster. Pfizer, which has run ads during the Big Game for the past two years, ...

Pfizer beat on 2025 sales and beat on earnings -- but still delivered a loss. Pfizer reaffirmed 2026 sales and earnings guidance for under $3 per share. Analysts forecast the pharmaceuticals giant ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Pfizer took its next steps Tuesday in its attempted resurrection in the ...

Pfizer is one of the world's largest pharmaceutical companies. It has a long history of navigating the competitive and technically complex industry. Pfizer's stock has lost half its value since late ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + ...

Boltz Bags $28M Funding and Pfizer Partnership for Biomolecular AI Boost Your email has been sent Pfizer and Boltz have announced a collaboration aimed at expanding the use of advanced biomolecular AI ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. The Big Pharma is offering the California biotech up to $65 million in upfront, near ...

MARIN COUNTY, Calif. (KGO) -- As the demand for COVID-19 booster shots increases, we are getting reports of people showing up to local pharmacies and realizing their appointments were either canceled, ...

Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in 2026 than in 2025, as the drugmaker’s efforts to remake its business continue to ...

Pfizer Inc. is cutting hundreds of jobs in Switzerland as part of a multi-year program to reduce costs, according to people familiar with the matter. The US drugmaker will reduce its workforce in the ...